TRPC1 and hepatocellular carcinoma: Transient receptor potential canonical 1 (TRPC1) down-regulation has previously been shown to be associated with hepatocellular carcinoma cell proliferation [5], and therefore TRPC1 may exist as a potential novel drug target.